Denosumab biosimilar(Reliance Life Sciences)

地舒单抗生物类似药（Reliance Life Sciences）

Report date: 2022/03/01 18:08:47

Base Information

Drug NameDenosumab biosimilar(Reliance Life Sciences)
Drug Alias NameDenosuRelR-TPR-045
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesOsteoporosis, Postmenopausal
Global Approved IndicationsBone metastasesOsteoporosis, Postmenopausal
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2022/02/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesReliance Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesReliance Life Sciences
Inactive CompaniesN/A
Active IndicationsBone metastasesOsteoporosis, Postmenopausal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A